Although the U.S. healthcare industry has weathered the storm over the past couple of years, we may be reaching calmer waters in the coming months. Dry powder held by U.S. private equity investors has reached an all-time high, and with capital on the sideline ready to deploy, pressure to get deals done is on the rise.
With that backdrop, navigating the healthcare M&A landscape continues to be increasingly challenging, especially with an ever-evolving regulatory landscape. Bass, Berry & Sims has been closely following key legislative and regulatory efforts at both the state and federal levels. In this article, we examine the impact they are having on private equity transactions in the healthcare industry.
Please see full publication below for more information.
